Eli Lil­ly swoops in to buy a small pro­tein drug de­vel­op­er and its glu­cose re­spon­sive in­sulin in $1B-plus deal

Eight months af­ter tak­ing the lead on an in­vest­ment in Pro­tomer Tech­nolo­gies and its glu­cose re­spon­sive in­sulin, Eli Lil­ly is com­ing back for the whole …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.